Global Information
회사소개 | 문의 | 비교리스트

세계의 액체 생검 시장(2020-2028년)

Global Liquid Biopsy Market Forecast 2020-2028

리서치사 Inkwood Research
발행일 2020년 07월 상품 코드 947605
페이지 정보 영문 248 Pages
가격
US $ 2,500 ₩ 2,995,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,594,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,391,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 액체 생검 시장(2020-2028년) Global Liquid Biopsy Market Forecast 2020-2028
발행일 : 2020년 07월 페이지 정보 : 영문 248 Pages

세계의 액체 생검 시장은 2020-2028년의 예측기간 동안 연평균 복합 성장률(CAGR) 20.50%의 성장이 예측됩니다. 시장 성장을 촉진하는 요인으로서 정밀의료의 성장, 정부의 이니셔티브 급증, 고령자의 암 증가, 액체 생검의 가능성 증가, 기술 발전을 들 수 있습니다.

세계의 액체 생검(Liquid Biopsy) 시장에 대해 조사 분석했으며, 시장 개요, 시장 역학, 부문별 시장 분석, 경쟁 상황 등에 대해 체계적인 정보를 제공합니다.

목차

제1장 조사 범위와 조사 방법

제2장 개요

제3장 시장 역학

  • 시장의 정의
  • 주요 시장 성장 촉진요인
  • 주요 시장 성장 억제요인

제4장 주요 분석

  • Porter's Five Forces 분석
  • 주요 사업
  • 규제 프레임워크
  • 기회 매트릭스
  • 벤더 상황
  • 주요 투자 인사이트

제5장 시장 : 치료 적응증별

  • 폐암
  • 유방암
  • 전립선암
  • 대장암
  • 악성 흑색종
  • 기타 유형의 암
  • 종양 이외의 적응증

제6장 시장 : 임상 응용별

  • 치료 모니터링
  • 예후 재발 모니터링
  • 치료 선택
  • 진단 및 검사

제7장 시장 : 바이오마커 유형별

  • 핵산
  • 단백질
  • 세포외 소포
  • 세포

제8장 시장 : 분석 플랫폼별

  • NGS
  • 마이크로어레이
  • PCR
  • 프로테오믹스
  • 기타

제9장 시장 : 분석 목적별

  • 조기 발견/검사
  • 치료 가이던스
  • 모니터링
  • 진단

제10장 시장 : 순환 바이오마커별

  • 순환 종양 DNA(ctDNA)
  • 순환 종양 세포(CTC)
  • Cell-free DNA(cfDNA)
  • 기타

제11장 시장 : 최종사용자별

  • 의사 연구실
  • 병원
  • 임상진단검사실

제12장 지역별 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 러시아
    • 벨기에
    • 폴란드
    • 기타 유럽
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주 및 뉴질랜드
    • 태국
    • 인도네시아
    • 베트남
    • 기타 아시아태평양
  • 기타 세계 지역
    • 라틴아메리카
    • 중동 및 아프리카

제13장 기업 개요

  • BECTON DICKINSON AND COMPANY(BD)
  • F HOFFMANN-LA ROCHE
  • BIO-RAD LABORATORIES INC
  • B BRAUN MELSUNGEN AG
  • BOSTON SCIENTIFIC CORPORATION
  • QIAGEN NV
  • PLANMECA OY
  • COOK MEDICAL INC
  • AD-TECH MEDICAL INSTRUMENT CORP
  • AGILENT TECHNOLOGIES INC
  • ARGON MEDICAL DEVICES INC
  • CINTEC MEDICAL LTD
  • FISCHER MEDICAL TECHNOLOGIES LLC
  • IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL
LSH 20.07.24

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - LIQUID BIOPSY
  • TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
  • TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
  • TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
  • TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 23: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 25: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 26: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 27: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 28: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2019
  • FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2019
  • FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2020-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2020-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2019
  • FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2020-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2020-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2020-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2019
  • FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2020-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2020-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2020-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2020-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2019
  • FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2020-2028 (IN $ MILLION)
  • FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2020-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2020-2028 (IN $ MILLION)
  • FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2019
  • FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2020-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2020-2028 (IN $ MILLION)
  • FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2020-2028 (IN $ MILLION)
  • FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2020-2028 (IN $ MILLION)
  • FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2019
  • FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS' OFFICE LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2020-2028 (IN $ MILLION)
  • FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 44: THE UNITED STATES LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 47: THE UNITED KINGDOM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 55: ASIA PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 64: REST OF ASIA PACIFIC LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

KEY FINDINGS

The global liquid bioscopy market is predicted to register a CAGR of 20.50% during the forecast period of 2020 to 2028. The primary factors propelling the market growth are growth in precision medicine, rising government initiatives, the growing pervasiveness of cancer in the older population, increasing potential of liquid biopsies, and technological advancements.

MARKET INSIGHTS

Due to rapid changes in consumer demands, diagnostic testing has been shifted from hospitals and commercial laboratories, to locations closer to the patient's home. This has resulted in minimizing the overall cost of testing. Most healthcare services in urban areas are delivered at home with a reduced focus on rural areas. Moreover, developing countries also have a high percentage of people residing in rural areas, with very few diagnostic centers and low accessibility. Thus, fatalities due to cancer are very high in rural environments. The increasing death toll can be attributed to a lack of awareness of the disease, leading to ignorance of diagnosis and treatment. Hence, it is anticipated that improved diagnostic tools, faster response times, easy availability of biopsy solutions at an inexpensive rate, and high amounts of research grants would lead to establishing numerous diagnostic centers, especially in rural areas and developing countries in the region. Consequently, the growing number of diagnostic centers are projected to offer a lucrative opportunity for biopsy solution providers and augment market growth.

REGIONAL INSIGHTS

Countries across the Asia Pacific, North America, Europe, and the rest of the world are analyzed to assess global liquid biopsy market growth. According to Inkwood Research, North America is estimated to garner the largest revenue share by the end of the forecast period. As a result of the increasing number of cancer cases, the demand for liquid biopsy in North America is projected to rise. Canada and the United States have superior biopsy technologies that specialize in detecting diseases at the early stages, thus reducing the countries' mortality rates.

COMPETITIVE INSIGHTS

As the global liquid biopsy market continues to emerge, regular and rapid developments are being witnessed. There are very few obstructions to innovations entering the market, resulting in medium to high levels of industry rivalry. Some of the established companies in the market include Cook Medical Inc, F Hoffmann-La Roche, Qiagen NV, Planmeca OY, Boston Scientific Corporation, Bio-Rad Laboratories, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISING GOVERNMENT INITIATIVES
    • 3.2.2. GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
    • 3.2.3. GROWING NUMBER OF DIAGNOSTIC CENTERS
    • 3.2.4. GROWTH OF PRECISION MEDICINE
    • 3.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • 3.2.6. RISING POTENTIAL OF THE LIQUID BIOPSY
    • 3.2.7. TECHNOLOGICAL ADVANCEMENT
  • 3.3. KEY RESTRAINTS
    • 3.3.1. LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
    • 3.3.2. POOR COMPENSATION STRUCTURES
    • 3.3.3. HIGH COST OF THE TEST
    • 3.3.4. LACK OF REIMBURSEMENT
    • 3.3.5. LACK OF SKILLED PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. KEY LIQUID BIOPSY INITIATIVES
  • 4.3. REGULATORY FRAMEWORK
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. LUNG CANCER
  • 5.2. BREAST CANCER
  • 5.3. PROSTATE CANCER
  • 5.4. COLORECTAL CANCER
  • 5.5. MELANOMA CANCER
  • 5.6. OTHER TYPES OF CANCER
  • 5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION

  • 6.1. TREATMENT MONITORING
  • 6.2. PROGNOSIS AND REOCCURRENCE MONITORING
  • 6.3. TREATMENT SELECTION
  • 6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE

  • 7.1. NUCLEIC ACID
  • 7.2. PROTEIN
  • 7.3. EXTRACELLULAR VESICLES
  • 7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM

  • 8.1. NGS
  • 8.2. MICROARRAY
  • 8.3. PCR
  • 8.4. PROTEOMICS
  • 8.5. OTHER ANALYSIS PLATFORMS

9. MARKET BY ANALYSIS PURPOSE

  • 9.1. EARLY DETECTION/SCREENING
  • 9.2. THERAPY GUIDANCE
  • 9.3. MONITORING
  • 9.4. DIAGNOSIS

10. MARKET BY PRODUCT

  • 10.1. CIRCULATING TUMOR DNA (CTDNA)
  • 10.2. CIRCULATING TUMOR CELLS (CTCS)
  • 10.3. CELL-FREE DNA (CFDNA)
  • 10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER

  • 11.1. PHYSICIANS' OFFICE LABORATORIES
  • 11.2. HOSPITALS
  • 11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. THE UNITED STATES
    • 12.1.2. CANADA
  • 12.2. EUROPE
    • 12.2.1. THE UNITED KINGDOM
    • 12.2.2. FRANCE
    • 12.2.3. GERMANY
    • 12.2.4. ITALY
    • 12.2.5. RUSSIA
    • 12.2.6. BELGIUM
    • 12.2.7. POLAND
    • 12.2.8. REST OF EUROPE
  • 12.3. ASIA PACIFIC
    • 12.3.1. JAPAN
    • 12.3.2. CHINA
    • 12.3.3. INDIA
    • 12.3.4. SOUTH KOREA
    • 12.3.5. AUSTRALIA & NEW ZEALAND
    • 12.3.6. THAILAND
    • 12.3.7. INDONESIA
    • 12.3.8. VIETNAM
    • 12.3.9. REST OF ASIA PACIFIC
  • 12.4. REST OF WORLD
    • 12.4.1. LATIN AMERICA
    • 12.4.2. MIDDLE EAST & AFRICA

13. COMPANY PROFILES

  • 13.1. BECTON DICKINSON AND COMPANY (BD)
  • 13.2. F HOFFMANN-LA ROCHE
  • 13.3. BIO-RAD LABORATORIES INC
  • 13.4. B BRAUN MELSUNGEN AG
  • 13.5. BOSTON SCIENTIFIC CORPORATION
  • 13.6. QIAGEN NV
  • 13.7. PLANMECA OY
  • 13.8. COOK MEDICAL INC
  • 13.9. AD-TECH MEDICAL INSTRUMENT CORP
  • 13.10. AGILENT TECHNOLOGIES INC
  • 13.11. ARGON MEDICAL DEVICES INC
  • 13.12. CINTEC MEDICAL LTD
  • 13.13. FISCHER MEDICAL TECHNOLOGIES LLC
  • 13.14. IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL
Back to Top
전화 문의
F A Q